Loading...
In Vitro Activities of CG400549, a Novel FabI Inhibitor, against Recently Isolated Clinical Staphylococcal Strains in Korea
The in vitro activities of CG400549, a novel FabI inhibitor, were compared to those of linezolid and commonly used antimicrobials against recent bacterial isolates. CG400549 had an MIC(90) of 0.5 μg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society for Microbiology (ASM)
2007
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1913239/ https://ncbi.nlm.nih.gov/pubmed/17420210 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01562-06 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|